Recent events
Recent events tied to this brand in public sources.
Back to profile15 entries
2023
Roche Pharma China and Sinopharm sign a strategic cooperation framework agreement
Roche Pharma China and Sinopharm Holding signed a strategic cooperation framework agreement at the China International Import Expo.
2022
Merck and Sinopharm sign molnupiravir cooperation framework
Merck and Sinopharm announced that they had signed a cooperation framework agreement. Under the agreement, Merck grants Sinopharm distribution and exclusive import rights in China for molnupiravir if the drug is approved there; the parties will also assess the feasibility of technology transfer.
2022
Brii Biosciences and Sinopharm form strategic commercialization partnership
Brii Biosciences announced that its controlled company, 腾盛华创, had entered a strategic partnership with Sinopharm to advance the China commercialization of the BRII-196/BRII-198 combination therapy, including drug reserves, distribution channels, and regional access.
2021
Hua Medicine and Sinopharm establish supply-chain partnership
Hua Medicine and Sinopharm signed a supply-chain strategic cooperation agreement covering logistics and warehousing, supply-chain management, and channel digitalization, to support commercialization of dorzagliatin in China after approval.
2021
Sinopharm entities and Bangladesh sign vaccine cooperation memo
China National Pharmaceutical Group subsidiaries China National Medicines Corporation and China National Biotec Group, together with Bangladesh's Ministry of Health and Family Welfare, signed a memorandum of cooperation on filling and packaging inactivated COVID-19 vaccines.
2021
Juyi Technology completes Series B financing
Juyi Technology completed a Series B financing of more than RMB 100 million, jointly led by Legend Capital and YuanBio Venture Capital, with other investors participating.
2021
Medical specialists warn against Sinopharm vaccine use in Sri Lanka
The Association of Medical Specialists warned against using the Sinopharm vaccine in Sri Lanka, citing an expert panel's conclusion that the available data were insufficient to determine its safety, efficacy and immunogenicity.
2021
Mingji Biotech completes RMB 300 million Series B financing
Mingji Biotech announced that it completed a Series B financing totaling RMB 300 million, led by CICC Qide Fund, with existing investor Lilly Asia Ventures and other institutions participating.
2021
Knightsbridge Circle offers a China-developed vaccine travel service
The Knightsbridge Circle offered a travel service for members and prospective members to travel to the UAE and receive a COVID-19 vaccine developed by China National Pharmaceutical Group, subject to membership or a stated fee and travel and accommodation costs.
2021
Sinopharm Holdings appoints Yu Qingming as board chairman
On January 14, Sinopharm Holdings announced that its board had elected Yu Qingming as board chairman, as well as chairman of the board’s strategy and investment committee and nomination committee.
2020
Summer Atlantic Capital signs strategic partnership with Sinopharm
Summer Atlantic Capital announced that it had signed a strategic partnership agreement with Sinopharm to introduce pharmaceutical and medical device technologies to mainland China. The agreement adds Sinopharm to Summer Atlantic Capital's network for evaluating medical technologies.
2020
Fosun Pharma and Sinopharm sign vaccine logistics partnership
Fosun Pharma and Sinopharm Holding signed a strategic logistics cooperation agreement for the BioNTech mRNA vaccine, including plans to jointly establish a vaccine cold-chain system and improve storage, transport and distribution services.
2020
JinFang Medicine completes Series B financing
JinFang Medicine announced that it had completed a Series B financing of nearly RMB 400 million, co-led by CDH Investments and Shenzhen Capital Group's healthcare fund, with other investors participating and existing investors increasing their investment.
2020
Sinopharm wins Best Southbound Stock Connect Company award
Sinopharm Holdings received the Best Southbound Stock Connect Company award at the fourth Golden Hong Kong Stocks annual selection.
2019
Guoyao Technology subsidiary agrees to acquire 40% of Wing Yin Holdings
Guoyao Technology announced that its wholly owned subsidiary, Zhongcai Enterprise Management, entered into an agreement on December 12 to acquire a 40% stake in Wing Yin Holdings for HK$41.6 million, paid through consideration shares.